CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Price, Quote, News and Overview
NASDAQ:CNTB - Nasdaq - US2075231017 - ADR - Currency: USD
CNTB Quote, Performance and Key Statistics
NASDAQ:CNTB (2/21/2025, 8:10:26 PM)
0.8701
+0.01 (+1.17%)
The current stock price of CNTB is 0.8701 USD. In the past month the price decreased by -18.68%. In the past year, price decreased by -29.55%.
CNTB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in San Diego, California and currently employs 81 full-time employees. The company went IPO on 2021-03-19. The company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.
Company Info
CONNECT BIOPHARMA HOLDINGS L
12265 El Camino Real, Suite 350
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 81
Company Website: https://www.connectbiopharm.com
Investor Relations: http://investors.connectbiopharm.com
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
What is the stock price of CONNECT BIOPHARMA HOLDINGS L today?
The current stock price of CNTB is 0.8701 USD. The price increased by 1.17% in the last trading session.
What is the ticker symbol for CONNECT BIOPHARMA HOLDINGS L stock?
The exchange symbol of CONNECT BIOPHARMA HOLDINGS L is CNTB and it is listed on the Nasdaq exchange.
On which exchange is CNTB stock listed?
CNTB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONNECT BIOPHARMA HOLDINGS L stock?
7 analysts have analysed CNTB and the average price target is 8.16 USD. This implies a price increase of 837.82% is expected in the next year compared to the current price of 0.8701. Check the CONNECT BIOPHARMA HOLDINGS L stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONNECT BIOPHARMA HOLDINGS L worth?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a market capitalization of 48.08M USD. This makes CNTB a Nano Cap stock.
How many employees does CONNECT BIOPHARMA HOLDINGS L have?
CONNECT BIOPHARMA HOLDINGS L (CNTB) currently has 81 employees.
What are the support and resistance levels for CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a resistance level at 0.99. Check the full technical report for a detailed analysis of CNTB support and resistance levels.
Is CONNECT BIOPHARMA HOLDINGS L (CNTB) expected to grow?
The Revenue of CONNECT BIOPHARMA HOLDINGS L (CNTB) is expected to grow by 15.06% in the next year. Check the estimates tab for more information on the CNTB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNTB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNTB, evaluating the profitability, health, valuation and growth aspects
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Sales and EPS estimates to see what analysts future expectations are.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Chart to make your own analysis
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Latest news and press-releases to stay up to date.
Does CONNECT BIOPHARMA HOLDINGS L (CNTB) stock pay dividends?
CNTB does not pay a dividend.
What is the Price/Earnings (PE) ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB)?
CONNECT BIOPHARMA HOLDINGS L (CNTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
What is the Short Interest ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
The outstanding short interest for CONNECT BIOPHARMA HOLDINGS L (CNTB) is 0.1% of its float. Check the ownership tab for more information on the CNTB short interest.
CNTB Technical Analysis
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTB. The financial health of CNTB is average, but there are quite some concerns on its profitability.
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 92.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.01% | ||
| ROE | -46.94% | ||
| Debt/Equity | 0 |
CNTB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CNTB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 73.94% and a revenue growth 15.06% for CNTB